Meningococcal Disease

Rosenstein, Nancy E.; Perkins, Bradley A.; Stephens, David S.; Popović, Tanja; Hughes, James M.

doi:10.1056/nejm200105033441807

Cited by 1,118 publications

(1,074 citation statements)

References 87 publications

Supporting

Mentioning

962

Contrasting

Unclassified

100

Order By: Relevance

“…Active hospital-based surveillance was performed in metropolitan Salvador and detected a mean annual incidence of 1.71 cases of meningococcal meningitis per 100 000 population, with a CFR of 8.1%. These rates are comparable with those seen in the USA and Europe (Bilukha and Rosenstein, 2005;Rosenstein et al, 1999Rosenstein et al, ,2001. As a caveat, rates of culture-positive meningococcal meningitis are likely to underestimate the true disease burden, which is expected to be higher than that encountered in developed countries, since case ascertainment may not have been complete and use of antibiotics prior to hospitalisation may have interfered with the efficiency of culture isolation.…”

Section: Discussionsupporting

confidence: 53%

“…However, in the USA and Europe, an elevated rate of meningococcal disease has been reported among teenagers and young adults (Cartwright et al, 2001;Rosenstein et al, 1999). In this situation, increased risk was associated with exposure to diverse strains of N. meningitidis during college attendance, especially for students residing in dormitories (Cartwright et al, 2001;Rosenstein et al, 2001). In contrast, meningococcal meningitis cases in Salvador were predominantly members of poor slum (favela) communities.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Hospital-based surveillance of meningococcal meningitis in Salvador, Brazil

Cordeiro

Neves

Ribeiro

et al. 2007

Transactions of the Royal Society of Tropical Medicine and Hygi

View full text Add to dashboard Cite

SummaryThis study aimed to describe the clinical, epidemiological and microbiological features of meningococcal meningitis in Salvador, Brazil. Between February 1996 and January 2001, a hospitalbased surveillance prospectively identified cases of culture-positive meningococcal meningitis. Demographic and clinical data were collected through interview and medical chart review. Antisera and monoclonal antibodies were used to determine the serogroup and serotype:serosubtype of the isolates, respectively. Surveillance identified a total of 408 cases of meningococcal meningitis, with a case fatality rate of 8% (32/397). The mean annual incidence for the 304 culture-positive cases residing in metropolitan Salvador was 1.71 cases per 100 000 population. Infants <1 year old presented the highest incidence (14.7 cases per 100 000 population). Of the 377 serogrouped isolates, 82%, 16%, 2% and 0.3% were serogroups B, C, W135 and Y, respectively. A single serotype:serosubtype (4,7:P1.19,15) accounted for 64% of all cases. Continued surveillance is necessary to characterise strains and to define future prevention and control strategies.

show abstract

Section: Discussionsupporting

confidence: 53%

Section: Discussionmentioning

confidence: 99%

Hospital-based surveillance of meningococcal meningitis in Salvador, Brazil

Cordeiro

Neves

Ribeiro

et al. 2007

Transactions of the Royal Society of Tropical Medicine and Hygi

View full text Add to dashboard Cite

show abstract

“…1,2 The highest incidence of this disease occurs in infants in their first year of life, but a second peak occurs in adolescents, 3,4 and higher case fatality rates are generally reported in this age group. The vast majority of IMD can be attributed to infection by one of 5 immunologically-distinct serogroups: A, B, C, W and Y.…”

Section: Introductionmentioning

confidence: 99%

Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents

Sáez-Llorens

Vaca²,

Abarca

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

This phase 2 study assessed the immunogenicity, safety, and reactogenicity of investigational formulations of meningococcal ABCWY vaccines, consisting of recombinant proteins (rMenB) and outer membrane vesicle (OMV) components of a licensed serogroup B vaccine, combined with components of a licensed quadrivalent meningococcal glycoconjugate vaccine (MenACWY-CRM). A total of 495 healthy adolescents were randomized to 6 groups to receive 2 doses (Months 0, 2) of one of 4 formulations of rMenB antigens, with or without OMV, combined with MenACWY-CRM, or 2 doses of rMenB alone or one dose of MenACWY-CRM then a placebo. Immunogenicity was assessed by serum bactericidal assay with human complement (hSBA) against serogroups ACWY and serogroup B test strains; solicited reactions and any adverse events (AEs) were assessed. Two MenABCWY vaccinations elicited robust ACWY immune responses, with higher seroresponse rates than one dose of MenACWY-CRM. Bactericidal antibody responses against the rMenB antigens and OMV components were highest in subjects who received 2 doses of OMV-containing MenABCWY formulations, with 68% of subjects achieving hSBA titers 5 against each of the serogroup B test strains. After the first dose, solicited local reaction rates were higher in the MenABCWY or rMenB groups than the MenACWY-CRM group, but similar across groups after the second dose, consisting mainly of transient injection site pain. Fever ( 38.0 C) was rare and there were no vaccine-related serious AEs. In conclusion, investigational MenABCWY formulations containing OMV components elicited highly immunogenic responses against meningococcal serogroups ACWY, as well as serogroup B test strains, with an acceptable safety profile. [NCT01210885]

show abstract

“…No vaccine is available for the prevention of infections by MenB, which is responsible for up to 80% of meningococcal infections in developed countries (4). The MenB CP is an ideal target for immunization strategies, but it mostly shares epitopes with human tissue and is therefore nonimmunogenic.…”

Section: Discussionmentioning

confidence: 99%

“…Serogroups A, B, C, W135, and Y account for Ͼ95% of infections. Serogroup A strains cause epidemics in sub-Saharan Africa, whereas serogroups B, C, and Y predominate in Europe and North America (4). Effective vaccines consisting of CP or CP-protein conjugates are available for the prevention of infections caused by group A, C, Y, and W135 strains (5,6).…”

mentioning

confidence: 99%

Peptide Mimics of the Group B Meningococcal Capsule Induce Bactericidal and Protective Antibodies after Immunization

Passo¹,

Romeo²,

Pernice³

et al. 2007

The Journal of Immunology

View full text Add to dashboard Cite

Neisseria meningitidis serogroup B (MenB) is a leading cause of sepsis and meningitis in children. No vaccine is available for the prevention of these infections because the group B capsular polysaccharide (CP) (MenB CP) is unable to stimulate an immune response, due to its similarity with human polysialic acid. Because the MenB CP bears both human cross-reactive and non-cross-reactive determinants, we developed immunogenic peptide mimics of the latter epitopes. Peptides were selected from phage display libraries for their ability to bind to a protective anti-MenB CP mAb. One of these peptides (designated 9M) induced marked elevations in serum bactericidal activity, but not polysialic acid cross-reacting Abs, after gene priming followed by carrier-conjugate boosting. Moreover, the occurrence of bacteremia was prevented in infant rats by administration of immune sera before MenB challenge. 9M is a promising lead candidate for the development of an effective and affordable anti-MenB vaccine.

show abstract

Meningococcal Disease

Cited by 1,118 publications

References 87 publications

Hospital-based surveillance of meningococcal meningitis in Salvador, Brazil

Hospital-based surveillance of meningococcal meningitis in Salvador, Brazil

Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents

Peptide Mimics of the Group B Meningococcal Capsule Induce Bactericidal and Protective Antibodies after Immunization

Contact Info

Product

Resources

About